The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

George J. Brewer

Deptartment of Human Genetics

University of Michigan

Ann Arbor



Name/email consistency: high



  • Deptartment of Human Genetics, University of Michigan, Ann Arbor, USA. 1998 - 2010
  • Department of Human Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA. 2009
  • University of Michigan Medical School, Departments of Human Genetics and Internal Medicine, G061XMBNI, Ann Arbor, USA. 2009
  • University of Michigan School of Medicine, Ann Arbor 48109-0618, USA. 2001


  1. Subclinical zinc deficiency in Alzheimer's disease and Parkinson's disease. Brewer, G.J., Kanzer, S.H., Zimmerman, E.A., Molho, E.S., Celmins, D.F., Heckman, S.M., Dick, R. Am. J. Alzheimers. Dis. Other. Demen (2010) [Pubmed]
  2. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases. Brewer, G.J. Metallomics (2009) [Pubmed]
  3. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Brewer, G.J., Askari, F., Dick, R.B., Sitterly, J., Fink, J.K., Carlson, M., Kluin, K.J., Lorincz, M.T. Transl. Res (2009) [Pubmed]
  4. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Brewer, G.J. Expert. Opin. Investig. Drugs (2009) [Pubmed]
  5. Drug development for orphan diseases in the context of personalized medicine. Brewer, G.J. Transl. Res (2009) [Pubmed]
  6. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease. Brewer, G.J. J. Am. Coll. Nutr (2009) [Pubmed]
  7. The risks of free copper in the body and the development of useful anticopper drugs. Brewer, G.J. Curr. Opin. Clin. Nutr. Metab. Care (2008) [Pubmed]
  8. How reliable and robust are current biomarkers for copper status?--comments by Brewer and Althaus. Brewer, G.J., Althaus, J. Br. J. Nutr. (2008) [Pubmed]
  9. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Brewer, G.J. Exp. Biol. Med. (Maywood) (2007) [Pubmed]
  10. A brand new mechanism for copper toxicity. Brewer, G.J. J. Hepatol. (2007) [Pubmed]
  11. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. Brewer, G.J., Dick, R., Zeng, C., Hou, G. J. Inorg. Biochem. (2006) [Pubmed]
  12. Novel therapeutic approaches to the treatment of Wilson's disease. Brewer, G.J. Expert. Opin. Pharmacother (2006) [Pubmed]
  13. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Brewer, G.J., Askari, F., Lorincz, M.T., Carlson, M., Schilsky, M., Kluin, K.J., Hedera, P., Moretti, P., Fink, J.K., Tankanow, R., Dick, R.B., Sitterly, J. Arch. Neurol. (2006) [Pubmed]
  14. Fundamental problems lie ahead in the drug discovery and commercialization process: restructuring of the pharmaceutical industry and an improved partnership with academia are required. Brewer, G.J. J. Investig. Med. (2006) [Pubmed]
  15. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. Brewer, G.J. CNS. Drugs (2005) [Pubmed]
  16. Wilson's disease: clinical management and therapy. Brewer, G.J., Askari, F.K. J. Hepatol. (2005) [Pubmed]
  17. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Brewer, G.J. Curr. Cancer. Drug. Targets (2005) [Pubmed]
  18. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Brewer, G.J. Drug Discov. Today (2005) [Pubmed]
  19. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. Brewer, G.J., Dick, R., Ullenbruch, M.R., Jin, H., Phan, S.H. J. Inorg. Biochem. (2004) [Pubmed]
  20. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. Brewer, G.J., Ullenbruch, M.R., Dick, R., Olivarez, L., Phan, S.H. J. Lab. Clin. Med. (2003) [Pubmed]
  21. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Brewer, G.J., Hedera, P., Kluin, K.J., Carlson, M., Askari, F., Dick, R.B., Sitterly, J., Fink, J.K. Arch. Neurol. (2003) [Pubmed]
  22. Copper in medicine. Brewer, G.J. Curr. Opin. Chem. Biol (2003) [Pubmed]
  23. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. Brewer, G.J. J. Cell. Mol. Med. (2003) [Pubmed]
  24. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Brewer, G.J. Exp. Biol. Med. (Maywood) (2001) [Pubmed]
  25. Zinc acetate for the treatment of Wilson's disease. Brewer, G.J. Expert. Opin. Pharmacother (2001) [Pubmed]
  26. Recognition, diagnosis, and management of Wilson's disease. Brewer, G.J. Proc. Soc. Exp. Biol. Med. (2000) [Pubmed]
  27. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Brewer, G.J., Johnson, V.D., Dick, R.D., Hedera, P., Fink, J.K., Kluin, K.J. Hepatology (2000) [Pubmed]
  28. Wilson's Disease. Brewer, G.J. Curr. Treat. Options. Neurol (2000) [Pubmed]
  29. Wilson disease and canine copper toxicosis. Brewer, G.J. Am. J. Clin. Nutr. (1998) [Pubmed]
WikiGenes - Universities